Lausanne

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 8, 2021
Neurodegeneration, Dementia, AD, Hoffmann-La Roche, USD, Leadership, AU, NASDAQ, CEO, CH, GB, JP, RU, Acquisition, GLOBE, NO, Therapy, Genentech, Patient, Vaccine

LAUSANNE, Switzerland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended September 30, 2021 and provided a corporate update.
  • Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in Alzheimers disease (AD).
  • Announced that the Swiss Economic Forum (SEF) awarded AC Immune Co-Founder and CEO Prof. Andrea Pfeifer with the SEF.WomenAward for CEO of the Year .
  • SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU.

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases

Retrieved on: 
Thursday, November 4, 2021
Research, Perelman School of Medicine at the University of Pennsylvania, University, AU, Industry, Neurodegeneration, NO, CH, Pathology, Hoffmann-La Roche, Partnership, PET, PMID, NASDAQ, Neuroprotection, AC, GB, Genentech, Eli Lilly and Company, Center, RU, Aggregation, Brain, Precision medicine, FTLD, Company, CEO, Penn, Alzheimer's disease, Amyotrophic lateral sclerosis, Janssen Pharmaceuticals, GLOBE, JP, ALS, DNA, Vaccine, Pharmaceutical industry

The partnership is focused on studying the pathological mechanism of transactive response DNA binding protein 43 kDa (TDP-43) misfolding, aggregation and cell-to-cell transmission.

Key Points: 
  • The partnership is focused on studying the pathological mechanism of transactive response DNA binding protein 43 kDa (TDP-43) misfolding, aggregation and cell-to-cell transmission.
  • These results confirm the existence of distinct pathogenic TDP-43 species and have been published in Neuropathology and Applied Neurobiology1.
  • In extending the collaboration with Penn, we aim to further understand the role of these distinct pathogenic TDP-43 species in the different TDP-43 proteinopathies.
  • Our collaboration with AC Immune shows why industry sponsorship of academic research is vital for funding studies to advance our understanding into such an important target as TDP-43.

New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021

Retrieved on: 
Tuesday, November 2, 2021
Safety, AU, Neurodegeneration, NO, CH, Hoffmann-La Roche, Patient, NASDAQ, AC, GB, Genentech, Interim, Eli Lilly and Company, RU, Conference, Precision medicine, Company, AD, Janssen Pharmaceuticals, GLOBE, JP, Clinical trial, Pharmaceutical industry

LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimers disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimers Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimers disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimers Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.
  • Title: ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimers Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity
    Title: ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimers disease: Results of a phase 2, randomized, double-blind, placebo-controlled study
    AC Immune SAis clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark ofAC Immune SAin CN, CH, GB, JP, and NO.

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

Retrieved on: 
Friday, October 29, 2021
Dermatology, Merck, CH, University of Lausanne, Public policy, GB, Gebert, COVID-19, University of St. Gallen, Acquisition, GLOBE, Neurodegeneration, HIV, Diagnosis, Physician, Swiss National Bank, Honorary degree, RU, Company, World Bank, JP, Leo Pharma, Science, Neurology, AU, Industry, Royal college, University of Zurich, Medical director, NO, Drug development, AC, 2007 Swiss Federal Council election, Genentech, Eli Lilly and Company, Precision medicine, World, Royal College of Physicians, Janssen Pharmaceuticals, EGM, Board of directors, Federal Council, University, Hoffmann-La Roche, NASDAQ, Â, Novartis, Board, Schindler Elevator Corporation, Medical device, Management, Pharmaceutical industry, Medicine

LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.

Key Points: 
  • Dr. Shaw and Prof. Btler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.
  • We also extend our sincere thanks to Mr. Velasco and Dr. Bollmann, as their contributions as Directors helped to establish AC Immunes position as an industry leader.
  • I look forward to working with my fellow Directors to provide valuable insights and guidance as the Company advances its industry-leading strategy.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.

AC Immune to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Monday, October 25, 2021
AU, Neurodegeneration, NO, CH, Hoffmann-La Roche, NASDAQ, AC, GB, Genentech, Eli Lilly and Company, RU, Conference, Precision medicine, Company, CEO, Janssen Pharmaceuticals, GLOBE, JP, Pharmaceutical industry

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Key Points: 
  • LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.
  • The fireside chat will be available on-demand for attendees during the virtual conference beginning on November 18, 2021.
  • A replay of the fireside chat will also be available on the Events Page of AC Immunes website following the conferences conclusion.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence

Retrieved on: 
Thursday, October 7, 2021
University of Maryland, Baltimore, DME, Cornea, Abbott Laboratories, Wuhan University, Head, Cerebral edema, Retina, Investor, GLOBE, Growth, Safety, Medical Affairs Bureau, Diabetic retinopathy, Bayer, Johns Hopkins University, University, Johnson & Johnson, Duane syndrome, Eye disease, CEO, Sanofi, Alcon, Leadership, Eye, Patient, Medical device, Film, Pharmaceutical industry, Fine chemical

LAUSANNE, Switzerland, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oculis S.A., (Oculis) a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Dr. Joanne Chang, M.D., Ph.D., as Chief Medical Officer and Head of Portfolio Management. Dr. Chang brings unique R&D and medical affairs expertise given her experience in multiple geographies (U.S., China and globally), as well as a deep portfolio expertise in Ophthalmology covering all key areas such as cornea, retina, and gene therapy.

Key Points: 
  • Oculis also announces the opening of a new office in Hong Kong to broaden the companys development and commercial capabilities in Greater China and Asia, a strategically important region.
  • Dr. Chang will be based in the Hong Kong office and will have global responsibility for Medical Affairs and Corporate Portfolio Management.
  • Joanne brings global industry and operational expertise as well as strong leadership, which will be key as our late-stage product candidates start their Phase 3 trials.
  • Dr. Chang brings to Oculis more than 20 years of global experience in medical and regulatory affairs, clinical development, health economics and market access.

Davos Alzheimer's Collaborative, World Economic Forum Announce Major Milestones in the Global Fight Against Alzheimer’s Disease

Retrieved on: 
Tuesday, September 21, 2021
Mental Health, Managed Care, General Health, Hospitals, Science, Family, Nursing, Consumer, Clinical Trials, Health, Other Science, Research, Other Health, Other Consumer, Parenting, Pharmaceutical, Seniors, Goal, Coalition for Epidemic Preparedness Innovations, Public health, Growth, Johns Hopkins University, Vaccine, Epidemic, Data science, IHCC, Health, National, Multimedia, Roche, World Economic Forum, World, Disease, Leadership, R&D, G20, Dementia, Global, Partnership, IRS, Eli Lilly and Company, Indian Computing Olympiad, Lausanne, Former, World Health Organization, Caregiver, National Institutes of Health, Developing country, Company, PRS, Risk, Global Alliance, Davos, Time, CEPI, WHO, DAC, Coalition, Biogen, Patient, Board, COVID-19, Research, GAVI, Pharmaceutical industry

The Davos Alzheimers Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimers disease.

Key Points: 
  • The Davos Alzheimers Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimers disease.
  • The progress made by the Davos Alzheimers Collaborative since its launch in January signals the urgent need for a collective global response to the growing public health crises of Alzheimers disease, said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum.
  • DAC intends to announce further progress toward these goals during the Lausanne VIII Workshop in November 2021 and the World Economic Forum annual meeting in January 2022.
  • Launched at the World Economic Forums 2021 meeting on The Davos Agenda, The Davos Alzheimers Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimers presents to patients, caregivers and healthcare infrastructures.

YouHodler Awards a Trip Around the World to the Winner of the Crypto Journey Competition

Retrieved on: 
Thursday, September 16, 2021
Crypto, XRP, APR, DASH, CEO, Fiat, HT, XLM, DOGE, NFT, BTC, Environment, Non-fungible token, GLOBE, LTC, ETH, Time, Cryptocurrency

Offering crypto services, YouHodler helps people to understand and utilize the benefits of crypto assets and to avoid zero and negative interest rates on their savings with traditional banks.

Key Points: 
  • Offering crypto services, YouHodler helps people to understand and utilize the benefits of crypto assets and to avoid zero and negative interest rates on their savings with traditional banks.
  • Unlocking the value of crypto assets, the team shares a mission of helping people stop passive holding and start using crypto assets right now.
  • YouHodlers solutions open up connections between crypto and the real world, allowing people to use their crypto assets without spending them.
  • In addition, they can exchange crypto, fiat and stablecoins and get instant cash and crypto loans with their crypto assets acting as collateral.

AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year

Retrieved on: 
Friday, September 3, 2021
RU, Economic Forum, AC, GB, Eli Lilly and Company, Neurodegeneration, CH, Genentech, Politics, Precision medicine, Company, AU, Janssen Pharmaceuticals, SEF, NO, Woman, Hoffmann-La Roche, CEO, Entrepreneurship, GLOBE, JP, NASDAQ, Disease, Pharmaceutical industry

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: I am honored to receive the first SEF.WomenAward for CEO of the Year, and proud to be seen as an example for the many talented women in Switzerland who are making their way in business.

Key Points: 
  • Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: I am honored to receive the first SEF.WomenAward for CEO of the Year, and proud to be seen as an example for the many talented women in Switzerland who are making their way in business.
  • Prof. Pfeifer continued: Neurodegenerative diseases such as Alzheimers are socially and economically devastating and represent one of the biggest global healthcare challenges of our time.
  • SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

AC Immune to Participate in Upcoming Virtual Investor Conferences in September

Retrieved on: 
Thursday, September 2, 2021
Company, AU, Neurodegeneration, AC, NO, CH, GLOBE, Hoffmann-La Roche, GB, JP, Genentech, Precision medicine, Eli Lilly and Company, RU, NASDAQ, CEO, Janssen Pharmaceuticals, Alpha-synuclein, Pharmaceutical industry

A webcast of the corporate presentation will be available on the Events Page of AC Immunes website.

Key Points: 
  • A webcast of the corporate presentation will be available on the Events Page of AC Immunes website.
  • AC Immune SAis clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.